CHRS Coherus BioSciences Inc.

19.27
+0.08  (+0%)
Previous Close 19.19
Open 19.02
Price To Book -321.17
Market Cap 1,344,351,663
Shares 69,763,968
Volume 716,182
Short Ratio
Av. Daily Volume 1,085,083
Stock charts supplied by TradingView

NewsSee all news

  1. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or "the Company", NASDAQ:CHRS), today announced that effective October 17, 2019, the compensation committee of the Company's

  2. Coherus BioSciences to Report Third Quarter Financial Results on November 6th

    REDWOOD CITY, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or "the Company", NASDAQ:CHRS), today announced that its third quarter 2019 financial results will be released after market

  3. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that effective September 19, 2019, the compensation committee of the company's board of directors

  4. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that effective August 21, 2019, the compensation committee of the company's board of directors granted 13

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 top-line data met endpoints August 2016. BLA filing due in 2020.
CHS-1420
Psoriasis
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
FDA approval announced November 2, 2018.
CHS-1701
Pegfilgrastim biosimilar

Latest News

  1. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or "the Company", NASDAQ:CHRS), today announced that effective October 17, 2019, the compensation committee of the Company's

  2. Coherus BioSciences to Report Third Quarter Financial Results on November 6th

    REDWOOD CITY, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or "the Company", NASDAQ:CHRS), today announced that its third quarter 2019 financial results will be released after market

  3. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that effective September 19, 2019, the compensation committee of the company's board of directors

  4. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that effective August 21, 2019, the compensation committee of the company's board of directors granted 13